I am pleased to provide you with a detailed update on BTC Health Limited's (ASX:BTC) investments, along with an operational update of BTC's wholly owned investee companies.
BTC Health Limited
The primary objective for BTC Speciality Health is to increase market share through organic growth. New products will continue to be sourced by BioImpact and will enable BTC Speciality Health to expand its product range within pain management and critical care.
BTC Health Limited (ASX:BTC) Acquires Exclusive Distribution Rights for Bronchitol(R) and Aridol(R) from Pharmaxis
BTC Health Limited (ASX:BTC) is pleased to announce its investee company, BioImpact Pty Ltd, has acquired exclusive distribution rights for specialty respiratory brands Bronchitol(R) and Aridol(R) from Pharmaxis (ASX:PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol(R) only).
BTC Health Limited (ASX:BTC) $2.5m Capital Raise to Acquire the Distribution Rights to Bronchitol(R) and Aridol(R)
BTC Health Limited (ASX:BTC) is pleased to announce the receipt of binding firm commitments for a $2.5 million private placement to fund the acquisition of exclusive distribution rights to Bronchitol(R) and Aridol(R) in Australia, New Zealand, Malaysia, Hong Kong and Singapore.
The board of Biotech Capital (ASX: BTC) announced that its investee company (Stem Cell Sciences plc ("SCS") has concluded an agreement with the US-Based company Lexicon Genetics ("Lexicon"). Lexicon is a biopharmaceutical company focused on the discovery and development of treatments for a range of human diseases primarily using its proprietary gene knock out technology.